Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its quarterly earnings results on Thursday. The company reported $0.18 EPS for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.30% and a net margin of 33.85%.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS CHGCY traded down $0.30 during trading on Thursday, hitting $20.33. 89,914 shares of the company were exchanged, compared to its average volume of 189,677. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $26.00. The company has a market cap of $66.91 billion, a price-to-earnings ratio of 26.06 and a beta of 0.81. The firm’s fifty day moving average price is $21.62 and its 200 day moving average price is $22.43.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.